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COVID-19: Transforming Global Health

COMMENTARY
Neurological manifestations of COVID-19
Dureshahwar Kanwar,1 Abdul Mannan Baig,2 Mohammad Wasay3

Abstract
Coronavirus disease (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS CoV-2) has
turned out to be a formidable pandemic. Upcoming
evidence from confirmed cases of COVID-19 suggests an
anticipated incursion of patients with neurological
manifestations in the weeks to come. An expression of the
angiotensin-converting enzyme 2 (ACE 2), the cellular
receptor for SARS-CoV-2 over the glial cells and neurons
have made the brain a potential target. Neurotoxicity may
occur as a result of direct, indirect and post-infectious
complications. Attention to neurological deficits in COVID19 is fundamental to ensure appropriate, timely, beneficial
management of the affected patients. Most common
neurological manifestations seen include dizziness,
headache, impaired consciousness, acute cerebrovascular
disease, ataxia, and seizures. Anosmia and ageusia have
recently been hinted as significant early symptoms in
COVID-19. As cases with neurological deficits in COVID-19
emerge, the overall prognosis is yet unknown.
Keywords: Coronavirus, SARS-CoV-2, COVID-19, ACE 2,
Neurotoxicity, Brain, Seizures.
DOI: https://doi.org/10.5455/JPMA.20

Introduction
Neurological symptoms of coronavirus disease (COVID19) can be minimal at presentation but these can cause
monumental damage as silent contagious sources. With
the recent outbreak, there is a compelling need to
understand the potential of the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) to cause
neurological illness for proper diagnosis and therapeutic
decision making.
The SARS-CoV-2 particle resembles a medieval European
royal crown hence the name. The viral particle is enclosed
by an envelope, and protein spikes from its membrane
surface are responsible for interaction with host cell
receptor and resultant virulence and infectivity.
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Angiotensin-converting enzyme 2 (ACE 2) is the cellular
receptor for the new SARS-CoV-2 present on the brain and
glial tissue and thus this makes the central nervous
system (CNS) a potential target.1 There may be direct
infiltration of the CNS through the nasal epithelium and
entrance into the olfactory pathway with the subsequent
retrograde trans-synaptic spread. However, secondary
neurologic manifestations of COVID-19 are thought to be
the result of widespread dysregulation of homeostasis
and cytokine production with pulmonary, renal, hepatic,
and cardiovascular injury.2
Neurological symptoms fall into three main categories:
CNS, peripheral nervous symptoms (PNS) and skeletal
muscular symptoms.3 These clinical features may be the
presenting complaints or as more commonly seen arise
during the more frequently seen respiratory and febrile
illness. CNS manifestations most commonly seen include
dizziness, headache, impaired consciousness, acute
cerebrovascular disease, ataxia, and seizures. PNS
manifestations included taste impairment, smell
impairment and nerve pain. Skeletal muscular injury
manifestations include myalgias and rhabdomyolysis3
(Table-1). These are likely due to significantly elevated
pro-inflammatory cytokines in the serum and subsequent
downregulation of anti-inflammatory cytokines. Besides
coronavirus specific antibodies have been shown to
activate macrophages resulting in their migration into the
CNS and ultimately cause demyelination.4
The American Academy of Otolaryngology recently
Table-1: Neurological Clinical Abnormalities with coronavirus disease (COVID-19).
1. Central Nervous system:
a. Dizziness
b. Headache
c. Impaired consciousness
d.A cute cerebrovascular disease
e. Ataxia
f. Seizures
2. Peripheral Nervous System:
a. Anosmia
b. Ageusia
c. Neuralgia
3. Skeletal Muscle:
a. Myalgia
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proposed that anosmia, hyposmia, and dysgeusia should
be added to the list of COVID-19 screening symptoms and
urged precautionary isolation for individuals with these
symptoms, even in the absence of respiratory disease.5
In the largest study to date on 214 patients from Wuhan,
China, overall, 78 patients (36.4%) had neurologic
manifestations. The mean age of these patients was 52.7
years. Of these patients, 83 (38.8%) had at least 1 of the
following underlying disorders: hypertension (51
[23.8%]), diabetes (30 [14.0%]), cardiac or cerebrovascular
disease (15 [7.0%]), and malignancy (13 [6.1%]).3 A total of
126 patients (58.9%) had non-severe infection and 88
patients (41.1%) had severe infection according to their
respiratory status. Patients with severe infection were
more likely to develop neurologic manifestations,
especially acute cerebrovascular disease [5.7%];
conscious disturbance [14.8%] and skeletal muscle injury
[19.3%].3 Another recent report of 99 COVID-19 patients
in Wuhan also described neurological complications with
confusion (9%) and headache (8%) being most commonly
seen.6 Loss of smell and taste may precede respiratory
symptoms and suggest early neurological involvement.
Respiratory failure in the absence of severe lung
involvement may suggest neurogenic respiratory failure.7
Most neurologic manifestations occur early in the illness
(median time, 1-2 days). Of 6 patients with acute
cerebrovascular disease, 2 arrived at the emergency
department owing to the sudden onset of hemiplegia but
without any typical symptoms of fever, cough, anorexia,
and diarrhoea of COVID-19. Their lung lesions were found
by an emergent lung CT and were diagnosed as having
COVID-19 by a positive SARS-CoV-2 nucleic acid detection
in the later stage.3
Isolated new case reports of meningitis/encephalitis,8
haemorrhagic necrotizing encephalopathies,9 GuillainBarre syndrome,10 with COVID-19 are emerging every day
from all around the world. However, the neuroinvasive
nature of the human coronavirus and an association with
demyelination including multiple sclerosis11 and acute
disseminated encephalomyelitis has long been known.12
Laboratory findings in patients with COVID -19 include
high white blood cell counts, lower lymphocyte count,
and increased C-reactive protein. Severe infection have
corresponding higher D-dimer levels, increased lactate
dehydrogenase, alanine aminotransferase, and aspartate
aminotransferase levels, with elevated blood urea
nitrogen, creatinine levels, and creatinine kinase (CPK)
levels3 (Table-2).
Directed neurological workup depending upon the
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Table-2: Laboratory findings in coronavirus disease (COVID-19).
Non Severe Infection

Severe Infections

Dearanged white blood cell count
Raised neutrophil count
Lower lymphocyte count
Low Platelet count
Increased C reactive protein

Increased D dimer
Raised Creatine kinase
Increased Lactate dehydrogenase
Raised Alanine aminotransferase
Raised Aspartate aminotransferase
Raised Blood Urea Nitrogen
Raised Creatinine

clinical concern is required. A non-contrast CT Head to
exclude stroke in patients with possible or confirmed
COVID 19 should be reserved for times when actionable
information is likely to be obtained, or when a significant
change in the neurological examination is seen. A CT
angiogram of the head and neck may be required in cases
of subarachnoid hemorrhage. Additional studies
including MRI, echocardiograms and doppler should be
considered only if there is a high likelihood of changing
management as contamination issues are present. All
electroencephalogram (EEG) orders must be discussed
with EEG service attending and cases of seizures or
possibility of non-convulsive seizures (seen in up to 10%
of critically-ill patients) should ideally be performed with
disposable EEG leads. A cerebrospinal fluid (CSF)
examination may be required at the discretion of the
neurology consultant to exclude possible causes of
impaired consciousness. A lumbar puncture to look for
SARS-CoV-2 nucleic acid by using PCR is recommended in
highly suspicious cases.
An over-emphasis on the fact that nerve conduction
studies and needle electromyography are usually within
normal limits in the first 1-2 weeks of diseases of the
muscle and nerves cannot be made. No unnecessary
procedures should be performed as the machines may
serve as fomites and this needs close consideration.
Standard management of stroke with suspected COVID19 requires certain considerations. Patients needing
tissue plasminogen activator (tPA) during the one-hour
infusion may be monitored every 15 minutes by one
member of the stroke team in the patient's room to
conserve personal protective equipment (PPE) and limit
the potential for accidental exposure. In cases of
mechanical thrombectomy, groin checks can be done by
team members entering for other reasons every 4 hours
after the initial monitoring in the intervention radiology
suite.
Limiting exposure to potentially infected patients of
medical personnel and possible tele-neurology
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consultations when possible cannot be overstated.
Antiepileptic drugs that do not cause liver or renal
damage should be considered for control of seizures and
valproate should also be avoided in acute headache at
this time in the context of its known hepatotoxicity.
Also, the putative role of ACE2 in the pathophysiology of
COVID-19 has recently fueled concerns regarding the use
of non- steroidal anti-inflammatory drugs (NSAIDs) such
as ibuprofen, commonly used for headache. These are
known to induce up-regulation of ACE2 and, in theory,
may facilitate infection with COVID-19.13
The role of high dose intravenous immunoglobulins (IVIg)
in a recent case series of patients with COVID-19, all of
whom were successfully treated at the early stage of
clinical deterioration has been published with the
resultant initiation of a randomized controlled trial.14 This
may lead us to rethink the equal efficacy that has been
long established when treating patients with muscle or
nerve involvement with plasma exchange versus IVIg.
Practicing neurologists amid these critical times have
considerable unanswered queries in their minds
especially in underdeveloped countries. Do isolated
neurological symptoms warrant a COVID-19 testing there
and then before being a silent contagious source? Do we
take sufficient steps in educating our patients who are on
long-term use of immunosuppressants for illnesses like
myasthenia gravis, multiple sclerosis, and sarcoidosis, and
are now at a higher risk for COVID -19? Do Asians have an
additional risk for strokes in these times because of the
high prevalence of intracranial atherosclerosis here? Do
larger pharmaceuticals need to change direction in the
development of newer drugs and emphasise more on
antiviral agents considering that only a handful are
available? Is the COVID-19 here to stay? Will it become just
become another herpes, dengue, chikungunya infectioncausing neurological manifestations that we have been
commonly seeing over the past several years?

Conclusion
A cross-disciplinary unified approach is required in this
herculean endeavour by mankind to control this outbreak
as it still unfolds. Is this just a cursory glimpse of more
formidable events to be revealed in the future? Only time
will tell. Healthcare providers should keep a close watch
for isolated neurological symptoms at presentation when
evaluating patients for COVID-19 to assure both early
appropriate management and control of disease.
Research for new antiviral agents and the development of
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a possible vaccine is paramount and the time for action is
now. This is the only way to assure containment of this
suffering of humanity and its continued existence.
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